63365-23-1Relevant articles and documents
NEW BRAF INHIBITORS AS PARADOX BREAKERS
-
Page/Page column 38-39, (2021/06/22)
The invention provides a novel compound having the general formula (I) (I) wherein R1-R3 and X are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
Antifolate and Antibacterial Activities of 5-Substituted 2,4-Diaminoquinazolines
Harris, Neil V.,Smith, Christopher,Bowden, Keith
, p. 434 - 444 (2007/10/02)
A series of 5-substituted 2,4-diaminoquinazolines (3) has been synthesized and evaluated as inhibitors of the enzyme dihydrofolate reductase (DHFR) from both bacterial and mammalian sources.The best compounds (e.g. 53) show good activity against Escherichia coli DHFR, but there is no significant selectivity for the bacterial over the mammalian enzyme.The structure-activity relationships for enzyme inhibition appear to be complex and not amenable to simple analysis; a hypotesis to explain the observed qualitative structure-activity relationships is proposed.The inhibitory activities of the compounds against the growth of intact bacterial cells in vitro closely parallel those for the inhibition of the isolated bacterial enzymes, suggesting that their antifolate action is responsible for their antibacterial effects.Five of the compounds were tested for their ability to cure a systemic E. coli infection in the mouse, but they showed no therapeutic effects at their maximum tolerated doses.
Antisecretory oxamic acid esters
-
, (2008/06/13)
Variously substituted oxanilic acid esters possessing anti-secretory activity are useful anti-ulcer agents.